debio 1143
Small moleculeexperimental
Clinical trial activity
13 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started May 9, 2019 (NCT04122625)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Glioma · Phase 1
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 1
- Hypopharyngeal Neoplasms · Phase 2
- Laryngeal Neoplasms · Phase 2
- Mouth Neoplasms · Phase 2
- Neoplasms · Phase 1/Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 3
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)CC[C@H]2CC[C@@H](C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O- Mol. weight
- 561.73 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2158051 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06463184 | Phase 1 | Jul 22, 2024 | Merck Serono, University of South Florida |
| NCT06084845 | Phase 2 | Jan 10, 2024 | ECOG-ACRIN Cancer Research Group |
| NCT06056310 | Phase 1 | Jan 9, 2024 | Merck KGaA, Merck Serono |
| NCT06110195 | Phase 1 | Dec 31, 2023 | Merck Serono, University of Chicago |
| NCT05930938 | Phase 3 | Dec 12, 2023 | Groupe Oncologie Radiotherapie Tete et Cou |
| NCT06145412 | Phase 2 | Nov 16, 2023 | Memorial Sloan-Kettering Cancer Center |
| NCT05724602 | Phase 2 | Nov 15, 2023 | European Organisation for Research and Treatment of Cancer, Merck KGaA, University of Florence, University of Groningen |
| NCT05386550 | Phase 3 | Oct 6, 2022 | Merck KGaA, Merck Serono |
| NCT05519540 | Phase 1 | Sep 26, 2022 | Merck KGaA |
| NCT04962724 | Phase 1 | Aug 2, 2021 | Debiopharm |
| NCT04459715 | Phase 3 | Aug 7, 2020 | Debiopharm, GORTEC (Head and Neck Oncology and Radiotherapy Group) |
| NCT03871959 | Phase 1 | May 31, 2019 | Centre Leon Berard, Debiopharm, Merck |
| NCT04122625 | Phase 1/Phase 2 (Phase 2) | May 9, 2019 | Debiopharm |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 4 | 3 | 3 | 2019 |
| Merck KGaA | For profit | 4 | 1 | 3 | 2022 |
| Merck Serono | For profit | 4 | 2 | 2 | 2022 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2019 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 1 | 1 | 2024 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2023 |
| GORTEC (Head and Neck Oncology and Radiotherapy Group) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Groupe Oncologie Radiotherapie Tete et Cou | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Florence | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2024 |
14 organizations
Page 1 / 1